Digital healthcare solutions provider Daman has signed a global partnership agreement that will see it support more people living with Rheumatoid Arthritis (RA).
Daman has joined forces with pharmaceutical companies Gilead Sciences and Galapagos, allowing people with RA to access its innovative RheumaBuddy app.
The app is designed to encourage and promote better disease self-management and enable people with RA to track their symptoms.
The partnership includes 15 global markets and runs until September 15th 2021, with the possibility of extension.
Andreas Dam, CEO at Daman, said: “There is a huge unmet need among RA patients to give more holistic care offerings. The partnership enables us to take important steps in the direction – to the benefit of patients and society,” says Andreas Dam, CEO at Daman.
The news of the partnership comes one month after Daman started a three-year project to transform the RheumaBuddy app into a platform, benefiting all stakeholders in the rheumatology care eco-system.
Daman received a €1 million in funding from the EU and will now start to reach out for patients and patient organisations interested in joining workshops, being available for interviews and testing new releases of the application.
During the next six months, new features will be added – inspired by co-creation with patients.
These will include ‘My Plan & Goal’ – guiding and supporting healthy habits to help people with RA cope and improve their quality of life.